First in Man Study of ALX-0651, a Nanobody Inhibiting CXCR4

Clinical trial NCT01374503 · TERMINATED

Trial details

NCT number: NCT01374503
Sponsor: Ablynx, a Sanofi company
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Healthy Volunteers

Start date: 2011-06-01
Primary completion: 2012-01-01
Enrollment: 52

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.